Key Drivers
- Strong liquidity
- High gross-margin
- Large retained-losses
AIAI Summary
Omada has shifted from a high‑burn growth story to an execution‑focused, cash‑rich operator with positive Q4 net income, FY adjusted EBITDA and strong gross margins, meaning investors should now be betting on management's ability to convert membership growth into durable free cash flow rather than on scale alone. The critical risk/opportunity is membership persistence and GLP‑1 monetization—require 2–4 consecutive quarters of growing free cash flow and stable retention metrics (and controlled SG&A/R&D) to justify multiple expansion; failure here would likely trigger rapid valuation compression.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •High gross-margin
- •Large retained-losses
OMDA combines strong cash reserves, low leverage and improving quarterly profitability with high gross margins, but sizable R&D/SG&A and large cumulative losses keep FY results negative and valuation stretched.
Price Behavior
Key Price Behavior Insights:
- •Short‑term uptrend
- •Higher lows
- •Volatile swings
Over last month the stock climbed from $11.62 to $13.51 (~mid‑teens gain), sits slightly above the 21‑day SMA (~$13.31) with near‑term resistance at $14.80 and support around $11.17, but a pullback and material volatility increase mean‑reversion risk despite higher lows.
Sharp swings between low $11s and mid‑$14s with a pullback from the 3/16 peak to 3/20 indicating profit‑taking and mean‑reversion risk
Sentiment & News
Key News Insights:
- •Strong revenue/member growth
- •Positive adjusted EBITDA
- •GLP‑1 strategy launch
Omada posted robust 2025 operational growth (revenue +53%, members +55%), delivered Q4 net income and positive full‑year adjusted EBITDA, introduced a GLP‑1 Flex Care program amid mixed engagement, and guided ~22% revenue growth with modest 2026 adjusted EBITDA while analysts imply ~59.5% upside.
The results and conservative 2026 guidance support a bullish investment case—bolstered by analyst upside—but GLP‑1 engagement uncertainty could temper near‑term multiple expansion
Similar Companies in Healthcare
Other companies in the same sector with AI ratings